Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

Regulatory

August 21, 2025

Interim report Q2 2025

Read more

August 19, 2025

Invitation to Presentation of Egetis’ Second Quarter 2025 Report on August 21, 2025

Read more

August 18, 2025

Egetis reports progress towards US NDA submission for tiratricol

Read more

Upcoming event

September 16, 2025

Pareto Annual Healthcare Conference (Stockholm)

Latest presentation

August 21, 2025

Interim report Q2 2025 (webcast)

Latest Report

August 21, 2025

Interim report Q2 2025

Calendar and upcoming reports

November 7, 2025

Interim Report Q3 2025 (7:00am CET)

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]